<DOC>
	<DOCNO>NCT00080977</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill renal cell carcinoma ( kidney cancer ) cell . PURPOSE : This phase II trial study well high-dose intravenous interleukin-2 work treat patient metastatic renal cell carcinoma respond previous low-dose intravenous subcutaneous interleukin-2 .</brief_summary>
	<brief_title>High-Dose Intravenous Interleukin-2 Treating Patients With Metastatic Renal Cell Carcinoma ( Kidney Cancer ) That Has Not Responded Previous Low-Dose Intravenous Subcutaneous Interleukin-2</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate ( complete , partial , minor ) patient metastatic renal cell carcinoma fail prior low-dose intravenous subcutaneous interleukin-2 ( IL-2 ) treat high-dose intravenous IL-2 . - Determine overall survival , disease-free survival , time progression patient treat drug . - Determine toxicity drug patient . OUTLINE : This pilot study . Patients receive high-dose interleukin-2 IV every 8 hour 15 dos follow 7-10 day later another 15 dos ( course 1 ) . Patients assesed response 2 month initiation treatment . Patients respond stable disease receive second course therapy . Patients ongoing response receive subsequent course treatment absence unacceptable toxicity . Patients follow every 6 month survival . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Metastatic disease No pure papillary sarcomatoid variant Measurable disease Failed prior subcutaneous OR intravenous ( dose ≤ 50,000 IU/kg/day ) interleukin2 Documented disease progression No estimate hepatic replacement tumor &gt; 25 % CT scan MRI No tumor involve CNS major nerve PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 80100 % Life expectancy More 3 month Hematopoietic Platelet count ≥ 80,000/mm^3 No site ongoing bleeding Hepatic See Disease Characteristics Bilirubin ≤ 1.4 mg/dL AST ALT ≤ 3 time normal PT PTT INR ≤ 1.2 Hepatitis B surface antigen negative Hepatitis C virus negative No coagulation disorder Renal Creatinine ≤ 1.6 mg/dL Cardiovascular No ongoing ischemia* No cardiac dysfunction* No abnormal ejection fraction* NOTE : *A cardiac stress test indicate patient ≥ 50 year age patient possible cardiac disease suggest history , physical exam , electrocardiogram Pulmonary FEV_1 ≤ 65 % predicted* Vital capacity ≤ 65 % predicted* NOTE : *Pulmonary function test perform patient significant smoke history suspect pulmonary disease either history , physical exam , radiograph Other HIV negative No AIDS No systemic infection No malignancy except carcinoma situ No psychiatric illness would preclude study participation compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy No concurrent steroid Radiotherapy Not specify Surgery Not specify Other More 28 day since prior treatment renal cell cancer No concurrent immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>